Structure via PubChem · Public domain (PubChem)
(RS)-lenalidomide
Sign in to saveAlso known as CC-5013, CDC-501, 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, IMiD3, CDC 501, IMid-1, 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, Lenalidomide
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, various indolent lymphomas, and myelodysplastic syndromes (MDS). For multiple myeloma, it is a first-line treatment, and is given with dexamethasone. It is taken by mouth.
Key facts
- Drug.H
- 13
- Drug.N
- 3
- Drug.O
- 3
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 459429828
- Drug.image
- Lenalidomide enantiomers.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.chirality
- Racemic mixture
- Drug.tradename
- Revlimid, Linamide, others
- Drug.MedlinePlus
- a608001
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Lenalidomide
- Drug.pregnancy_AU
- X
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AX04
- Drug.legal_AU
- S4
via Wikipedia infobox
Chemical data
- Formula
- C13H13N3O3
- Molecular weight
- 259.26 g/mol
- IUPAC name
- 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
- SMILES
- C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
- InChIKey
- GOTYRUGSSMKFNF-UHFFFAOYSA-N
- XLogP
- -0.5
- Polar surface area
- 92.5 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
57 papers- Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.Blood · 2020
- Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.The Lancet. Haematology · 2022
- Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.Blood · 2025
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.Lancet (London, England) · 2017
- Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.The Lancet. Haematology · 2023
via PubMed
Wikidata facts
- Mass
- 259.095691
Show 5 more facts
- chemical formula
- C₁₃H₁₃N₃O₃
- World Health Organisation international non-proprietary name
- lenalidomide
- canonical SMILES
- C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
- defined daily dose
- 10
- Commons category
- Lenalidomide
Sources (7)
via Wikidata · CC0
~10 min read
Article
19 sectionsContents
- Medical uses
- Multiple myeloma
- Myelodysplastic syndromes
- Follicular Lymphoma
- Mantle cell lymphoma
- AL amyloidosis
- Adverse effects
- Teratogenicity
- Venous thromboembolism
- Stevens-Johnson syndrome
- FDA ongoing safety review
- Mechanism of action
- Synthesis
- History
- Society and culture
- Legal status
- Economics
- Price increases
- References
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, various indolent lymphomas, and myelodysplastic syndromes (MDS). For multiple myeloma, it is a first-line treatment, and is given with dexamethasone. It is taken by mouth.
Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping. Severe side effects include low blood platelets, low white blood cells, and blood clots. The dose may need to be adjusted in people with kidney problems. Lenalidomide is closely related to thalidomide, which is known to cause severe birth defects, so its use during pregnancy is very likely to harm the fetus.
Gallery (3)
Available in 22 languages
- Español
- Français
- Deutsch
- 中文
- 日本語
- Русский
- Português
- Italiano
- العربية
- Bahasa Indonesia
- Finnish
- Lithuanian
- Nederlands
- Odia
- Polski
- Serbian
- Serbian (Latin)
- Slovenian
Show 3 more
via Wikidata sitelinks · CC0